| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Email: |
|
| Products Intro: |
Product Name:TanezuMab
CAS:880266-57-9
Purity:99% HPLC Package:50Mg,100Mg,500Mg,1g,5g,10g,50g,100g,500g,1kg Remarks:XYA1257
|
| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Tanezumab
CAS:880266-57-9
Purity:ExactAb?, Validated, Carrier Free, Low Endotoxin, Azide Free Package:100μg Remarks:K13711
|
| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Tanezumab
CAS:880266-57-9
Purity:95% Package:100ug;500ug;1mg
|
|
| | Tanezumab Basic information |
| Product Name: | Tanezumab | | Synonyms: | tanezumab;Research Grade Tanezumab(DHB91701);Research Grade Tanezumab;Tanezumab (anti-NGF) | | CAS: | 880266-57-9 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tanezumab Structure]() |
| | Tanezumab Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Tanezumab Usage And Synthesis |
| Uses | Tanezumab (RN-624) is a humanized anti-NGF mAb with high affinity and specificity. Tanezumab blocks NGF binding to its receptors, p75 and TrkA, in the peripheral nervous system. Tanezumab can be used in studies of acute and chronic pain such as osteoarthritis, knee and neuralgia, as well as post-herpetic neuralgia[1][2]. | | in vivo | Tanezumab (10 mg/kg, sc, once a day for 8 weeks) exhibits antitumor activity, relieves nociceptive conduction in MiaPaCa-2 xenograft mouse models[3].
Tanezumab (2.5-5 mg/kg, sc, once a week for 4 weeks) exhibits anti-inflammatory and analgesic effects in rats Kashin-Beck Disease models[4]. | Animal Model: | MiaPaCa-2 xenograft mouse models[3] | | Dosage: | 10 mg/kg | | Administration: | sc, once a day for 8 weeks | | Result: | Reduced the tumor volume and invasive nerve diameter.
Alleviated hindlimb dysfunction. |
| Animal Model: | Sprague-Dawley rat Kashin-Beck Disease models[4] | | Dosage: | 2.5-5 mg/kg | | Administration: | sc, once a week for 4 weeks | | Result: | Increased the paw withdrawal mechanical threshold (PWT) and thermal paw withdrawal latency (PWL).
Decreased serum TNF-α and IL-1β levels. |
| | References | [1] Evans M, et al. Effects of tanezumab on satellite glial cells in the cervicothoracic ganglion of cynomolgus monkeys: A 26-week toxicity study followed by an 8-week recovery period. Auton Neurosci. 2019 May;218:51-53. DOI:10.1016/j.autneu.2019.02.004
[2] Mantyh P, et al. a humanized anti-nerve growth factor antibody for the treatment of pain[J]. The Journal of Pain, 2009, 10(4): S44.
[3] Peng T, et al., Nerve Growth Factor (NGF) Encourages the Neuroinvasive Potential of Pancreatic Cancer Cells by Activating the Warburg Effect and Promoting Tumor Derived Exosomal miRNA-21 Expression. Oxid Med Cell Longev. 2022 Oct 15;2022:8445093. DOI:10.1155/2022/8445093
[4] Haifan W, et al. Nerve growth factor monoclonal antibody Tanezumab alleviates Kashin-Beck Disease Rat pain by impacting DRG signal transduction[J]. 2023. |
| | Tanezumab Preparation Products And Raw materials |
|